Neurodevelopmental Impairment at Two Years in Premature Infants with Prolonged Patency of Ductus Arteriosus after a Conservative Approach

Am J Perinatol. 2021 Apr;38(5):449-455. doi: 10.1055/s-0039-1697674. Epub 2019 Oct 10.

Abstract

Objective: The study aims to assess the impact on neurodevelopmental outcomes of a prolonged hemodynamically significant patent ductus arteriosus (PDA) after a conservative treatment.

Study design: This involves the study of two cohorts of preterm infants 23 to 29 weeks gestation, before (n = 29) and after (n = 54) a conservative approach of PDA. We compared survival, major outcomes, and neurodevelopmental impairment (NDI) at 2 years and analyzed NDI in the conservative cohort according to the duration of the PDA.

Results: Conservative cohort received less medical (31.5%) and surgical treatment (7.4%) and had more days of PDA (59 days in 24-26 weeks and 22 days in 27-29 weeks; p < 0.001) in comparison with control cohort (19 days in 24-26 weeks and 11 days in 27-29 weeks; p = 0.688). Mortality, survival-without-morbidity at discharge, and NDI at 2 years were similar between the two groups (p = 0.732). In the multivariate analysis PDA >28 days was not related to worse outcomes at discharge (p = 0.296) or less survival-without-NDI at 2 years (p = 0.498).

Conclusion: Until randomized trials prove the benefit of attempting to close the PDA with ibuprofen in the first week of life, conservative management may be a reasonable option.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child, Preschool
  • Conservative Treatment
  • Ductus Arteriosus, Patent / drug therapy*
  • Ductus Arteriosus, Patent / surgery*
  • Female
  • Gestational Age
  • Humans
  • Ibuprofen / therapeutic use
  • Infant
  • Infant Mortality*
  • Infant, Newborn
  • Infant, Premature / growth & development*
  • Male
  • Multivariate Analysis
  • Neurodevelopmental Disorders / epidemiology
  • Neurodevelopmental Disorders / etiology*
  • Prospective Studies
  • Regression Analysis
  • Spain
  • Treatment Outcome

Substances

  • Ibuprofen